ABT Abbott Laboratories
FY2025 10-K
Abbott Laboratories (ABT) filed its fiscal year 2025 10-K annual report with the SEC on Feb 20, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model centered on healthcare products and medical technologies, with no new product lines detailed in 2026 filing
- • Notable new segment emphasis: merger agreement dated November 19, 2025 with Exact Sciences Corporation
Management Discussion & Analysis
- • Revenue $44.2B in 2025, up 5.7% YoY excluding foreign exchange impact
- • Operating margin 18.2% in 2025 vs 16.3% in 2024; Medical Devices margin 33.7% vs 32.4%
Risk Factors
- • IRS tax disputes over 2017-2020 SNODs totaling $1.05B contested, involving income reallocation between U.S. and foreign affiliates
- • Malaysian tax authorities assessed $413M capital gains tax on 2023 intercompany share sale; Penang High Court upheld, Abbott appealed in 2025
Financial SummaryXBRL
Revenue
$44.3B
Net Income
$6.5B
Operating Margin
18.2%
Net Margin
14.7%
ROE
12.5%
Total Assets
$86.7B
EPS (Diluted)
$3.72
Operating Cash Flow
$9.6B
Source: XBRL data from Abbott Laboratories FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Abbott Laboratories
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.